Drug Pricing

DXB signs $230M Commercialisation Deal for ~20% of the global market

Next Investors Oct 05, 2023

Our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB) has secured a $230M commercialisation deal with Advanz Pharmaceuticals for its Phase 3 drug targeting FSGS, a deal made before key trial results and a major ~$10.8M upfront payment in cash.

What could commercialisation actually look like for DXB?

Next Investors Mar 06, 2023

The sparsentan drug, which recently received accelerated FDA approval, and priced at US$120,000 per year, per patient, could act as a benchmark for Dimerix (ASX:DXB) pricing and potential deal value in negotiations with major pharmaceutical companies.